中生北控生物科技股份有限公司

BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION*

(Incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

INTERIM RESULTS ANNOUNCEMENT FOR THE THREE MONTHS AND SIX MONTHS ENDED 30 JUNE 2011

CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET (THE "GEM") OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")

GEM has been positioned as a market designed to accommodate companies to which a high investment risk may be attached. In particular, companies may list on GEM with neither a track record of profitability nor any obligation to forecast future profitability. Furthermore, there may be risks arising out of the emerging nature of companies listed on GEM and the business sectors or countries in which the companies operate. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement, for which the directors (the "Directors") of Biosino Bio-Technology and Science Incorporation (the "Company") collectively and individually accept full responsibilities, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM (the "GEM Listing Rules") of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement in this announcement misleading.

* *For identification purposes only*

The Board of Directors (the "Board") of the Company announced the unaudited consolidated income statement of the Group for the three months and six months ended 30 June 2011 and the unaudited condensed consolidated statement of financial position of the Group as at 30 June 2011, together with the comparative figures in 2010, as follows:

CONDENSED CONSOLIDATED INCOME STATEMENT

For the three months and six months ended 30 June 2011

		Three months ended 30 June		**Six months ended 30 June**	
		2011	2010	**2011**	2010
		Unaudited	Unaudited	**Unaudited**	Unaudited
	Notes	***RMB'000***	*RMB'000*	***RMB'000***	*RMB'000*
REVENUE	2, 3	**61,031**	59,770	**107,930**	104,706
Cost of sales		**(23,633)**	(18,672)	**(42,273)**	(33,103)
Gross profit		**37,398**	41,098	**65,657**	71,603
Other income and gains		**590**	365	**2,197**	2,022
Selling and distribution expenses		**(16,288)**	(12,828)	**(26,330)**	(26,209)
Administrative expenses		**(10,885)**	(13,919)	**(22,982)**	(24,432)
Research and development expenses		**(5,268)**	(5,092)	**(9,293)**	(9,445)
Other expenses		**(12)**	(5)	**(12)**	(5)
PROFIT FROM OPERATING ACTIVITIES	4	**5,535**	9,619	**9,237**	13,534
Finance costs	5	**(201)**	(109)	**(460)**	(271)
Share of losses of associates		**(48)**	(127)	**(192)**	(228)
PROFIT BEFORE TAX		**5,286**	9,383	**8,585**	13,035
Income tax expense	6	**(1,348)**	(1,659)	**(2,189)**	(2,439)
PROFIT FOR THE PERIOD		**3,938**	7,724	**6,396**	10,596
Attributable to:					
Owners of the parent		**3,688**	7,153	**6,201**	10,236
Non-controlling interests		**250**	571	**195**	360
		3,938	7,724	**6,396**	10,596
EARNINGS PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY	7				
– Basic (RMB)		**0.037**	0.072	**0.062**	0.102
– Diluted		**N/A**	N/A	**N/A**	N/A

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the three months and six months ended 30 June 2011

	Three months ended 30 June		**Six months ended 30 June**	
	2011	2010	**2011**	2010
	Unaudited	Unaudited	**Unaudited**	Unaudited
	RMB'000	*RMB'000*	***RMB'000***	*RMB'000*
PROFIT FOR THE PERIOD AND TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	**3,938**	7,724	**6,396**	10,596
Attributable to:				
Owners of the parent	**3,688**	7,153	**6,201**	10,236
Non-controlling interests	**250**	571	**195**	360
	3,938	7,724	**6,396**	10,596

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2011

	Notes	**30 June 2011 Unaudited** ***RMB'000***	31 December 2010 Audited *RMB'000*
ASSETS			
Non-current assets:			
Property, plant and equipment		**110,895**	102,723
Prepaid land lease payments		**6,639**	6,951
Goodwill		**308**	309
Other intangible assets		**5,611**	6,545
Investments in associates		**2,539**	2,731
Total non-current assets		**125,992**	119,259
Current assets:			
Prepaid land lease payments		**148**	177
Inventories		**36,347**	31,674
Trade and bills receivables	*9*	**48,257**	40,669
Prepayments, deposits and other receivables		**22,677**	10,805
Time deposits		**45,104**	41,300
Cash and cash equivalents		**135,752**	161,710
Total current assets		**288,285**	286,335
TOTAL ASSETS		**414,277**	405,594

	Notes	**30 June 2011 Unaudited** *RMB'000*	31 December 2010 Audited *RMB'000*
EQUITY AND LIABILITIES			
Equity attributable to owners of the parent:			
Issued capital	*10*	**131,304**	131,304
Reserves		**149,788**	143,587
Proposed final dividend		**–**	13,130
		281,092	288,021
Non-controlling interests		**36,982**	36,487
Total equity		**318,074**	324,508
Non-current liabilities:			
Deferred income		**13,118**	11,785
Corporate bonds		**20,647**	19,801
Total non-current liabilities		**33,765**	31,586
Current liabilities:			
Trade payables	*11*	**14,723**	10,592
Other payables and accruals		**44,949**	37,858
Taxes payable		**2,766**	1,050
Total current liabilities		**62,438**	49,500
Total liabilities		**96,203**	81,086
TOTAL EQUITY AND LIABILITIES		**414,277**	405,594

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2011

	Attributable to owners of the parent							
	Issued capital Unaudited *RMB'000*	Capital reserves# Unaudited *RMB'000*	Statutory reserves Unaudited *RMB'000*	Retained Profits Unaudited *RMB'000*	Proposed final dividend Unaudited *RMB'000*	Total Unaudited *RMB'000*	Non-controlling interests Unaudited *RMB'000*	Total equity Unaudited *RMB'000*
At 1 January 2010	100,018	31,126	32,308	34,543	13,502	211,497	27,027	238,524
Total comprehensive income for the period	–	–	–	10,236	–	10,236	360	10,596
Final 2009 dividend	–	–	–	–	(13,502)	(13,502)	–	(13,502)
Capital contributions from non-controlling interests	–	–	–	–	–	–	4,001	4,001
At 30 June 2010	100,018	31,126	32,308	44,779	–	208,231	31,388	239,619
At 1 January 2011	131,304	62,219+	35,843+	45,525+	13,130	288,021	36,487	324,508
Total comprehensive income for the period	–	–	–	6,201	–	6,201	195	6,396
Final 2010 dividend	–	–	–	–	(13,130)	(13,130)	–	(13,130)
Capital contributions from non-controlling interests	–	–	–	–	–	–	300	300
At 30 June 2011	131,304	62,219+	35,843+	51,726+	–	281,092	36,982	318,074

The capital reserves of the Group include non-distributable reserves of the Company and its subsidiaries created in accordance with the accounting and financial regulations of the PRC.

+ These reserve accounts comprise the consolidated reserves of RMB149,788,000 and RMB143,587,000 in the consolidated statement of financial position as at 30 June 2011 and 31 December 2010, respectively.

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

For the six months ended 30 June 2011

	Six months ended 30 June	
	2011	2010
	Unaudited	Unaudited
	RMB'000	*RMB'000*
Net cash (outflow)/inflow from operating activities	**(13,995)**	13,438
Net cash outflow from investing activities	**(9,095)**	(5,404)
Net cash (outflow)/inflow from financing activities	**(2,868)**	8,792
(Decrease)/increase in cash and cash equivalents	**(25,958)**	16,826
Cash and cash equivalents at beginning of period	**161,710**	95,345
Cash and cash equivalents at end of period	**135,752**	112,171

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. BASIS OF PREPARATION

The unaudited condensed consolidated financial statements for the three months and six months ended 30 June 2011 have been prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") (which include all Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("HKASs") and Interpretations) issued by the Hong Kong Institute of Certified Public Accountants, accounting principles generally accepted in Hong Kong and the disclosure requirements of the Hong Kong Companies Ordinance. The accounting policies and basis of preparation used in the preparation of the unaudited condensed consolidated financial statements are consistent with those used in the Company's audited financial statements for the year ended 31 December 2010.

2. SEGMENT INFORMATION

For management purposes, the group is organised into business units based on their products and has two reportable operating segments as follows:

(i) the in-vitro diagnostic reagent products segment manufactures, sells and distributes a variety of mono/double diagnostic reagent products; and

(ii) the pharmaceutical products segment manufactures, sells and distributes pharmaceutical products.

No operating segments have been aggregated to form the above reportable operating segments.

Management monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on operating profit or loss which in certain respects is measured differently from operating profit or loss in the consolidated financial statements. Group financing (including finance costs and finance revenue) and income taxes are managed on a group basis and are not allocated to operating segments.

The following tables present revenue and profit information regarding for the Group's operating segments for each of the six months ended 30 June 2011 and 2010:

Six months ended 30 June 2011

	In-vitro diagnostic reagent products Unaudited *RMB'000*	**Pharma-ceutical products Unaudited** *RMB'000*	**Eliminations Unaudited** *RMB'000*	**Total Unaudited** *RMB'000*
Segment revenue:				
Sales to external customers	**86,056**	**21,874**	**–**	**107,930**
Other income	**1,512**	**253**	**–**	**1,765**
Total	**87,568**	**22,127**	**–**	**109,695**
Segment results	**10,644**	**(1,839)**	**–**	**8,805**
Interest income				**432**
Profit from operating activities				**9,237**
Finance costs				**(460)**
Share of losses of associates	**(192)**	**–**	**–**	**(192)**
Profit before tax				**8,585**
Income tax expense				**(2,189)**
Profit for the period				**6,396**

Six months ended 30 June 2010

	In-vitro diagnostic reagent products Unaudited *RMB'000*	Pharma-ceutical products Unaudited *RMB'000*	Eliminations Unaudited *RMB'000*	Total Unaudited *RMB'000*
Segment revenue:				
Sales to external customers	73,679	31,027	–	104,706
Other income	1,520	19	–	1,539
Total	75,199	31,046	–	106,245
Segment results	10,587	2,464	–	13,051
Interest income				483
Profit from operating activities				13,534
Finance costs				(271)
Share of losses of associates	(228)	–	–	(228)
Profit before tax				13,035
Income tax expense				(2,439)
Profit for the period				10,596

3. REVENUE

Revenue, which is also the Group's turnover, represents the net invoiced value of goods sold, net of value-added tax and government surcharges, and after allowances for the goods returned and trade discounts.

An analysis of the Group's revenue for the three months and six months ended 30 June 2011 is as follows:

	Three months ended 30 June		**Six months ended 30 June**	
	2011 **Unaudited** ***RMB'000***	2010 Unaudited *RMB'000*	**2011** **Unaudited** ***RMB'000***	2010 Unaudited *RMB'000*
Sale of in-vitro diagnostic reagent products	**50,014**	43,117	**86,056**	73,679
Sale of pharmaceutical products	**11,017**	16,653	**21,874**	31,027
	61,031	59,770	**107,930**	104,706

4. PROFIT FROM OPERATING ACTIVITIES

The Group's profit from operating activities is arrived at after charging:

	Three months ended 30 June		**Six months ended 30 June**	
	2011	2010	**2011**	2010
	Unaudited	Unaudited	**Unaudited**	Unaudited
	RMB'000	*RMB'000*	***RMB'000***	*RMB'000*
Depreciation	**3,117**	3,315	**6,233**	6,584
Amortisation of know-how	**242**	22	**483**	299
Amortisation of prepaid land lease payments	**44**	44	**87**	87

5. FINANCE COSTS

	Three months ended 30 June		**Six months ended 30 June**	
	2011	2010	**2011**	2010
	Unaudited	Unaudited	**Unaudited**	Unaudited
	RMB'000	*RMB'000*	***RMB'000***	*RMB'000*
Interests on interest-bearing bank loans and corporate bonds	**201**	109	**460**	271

6. INCOME TAX EXPENSE

No provision for Hong Kong profits tax has been made as the Group has not generated any assessable profits in Hong Kong during the six months ended 30 June 2011 (2010: Nil). Taxes on profits assessable in the PRC, where the Group operates, have been calculated at the rates of tax prevailing in the PRC, based on existing legislation, interpretations and practices in respect thereof. According to the relevant PRC income tax law, the Company and certain of its subsidiaries, being registered as new and high technology enterprises in Beijing, are entitled to concessionary income tax rate of 15%, where appropriate.

	Three months ended 30 June		**Six months ended 30 June**	
	2011	2010	**2011**	2010
	Unaudited	Unaudited	**Unaudited**	Unaudited
	RMB'000	*RMB'000*	***RMB'000***	*RMB'000*
Current – Mainland, the PRC	**1,348**	1,659	**2,189**	2,439

7. EARNINGS PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY

The calculation of basic earnings per share for the three months and six months ended 30 June 2011 is based on the unaudited profit attributable to shareholders of the Company for the period and the weighted average number of 131,303,671 (2010: 100,017,528) ordinary shares in issue during the period.

No diluted earnings per share have been presented as there was no diluting event existed during the three months and six months ended 30 June 2011 (2010: Nil).

8. INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2011 (2010: Nil).

9. TRADE AND BILLS RECEIVABLES

Except for certain established customers of the Group for several instalment sales contracts entered into with payment terms ranging from two to four years, the credit period of the Group granted to its customers generally for a period ranging from 60 days to 180 days. The Group closely monitors overdue balances, and impairment is made when it is considered that amounts due may not be recovered. In view of the aforementioned and the fact that the Group's trade receivables relate to a large number of diversified customers, there is no significant concentration of credit risk. Trade and bills receivables are interest-free.

An aged analysis of the trade and bills receivables of the Group as at the balance sheet date based on invoice date, is as follows:

	30 June 2011 Unaudited ***RMB'000***	31 December 2010 Audited *RMB'000*
Within 3 months	**40,077**	35,432
4 to 6 months	**5,260**	3,292
7 to 12 months	**975**	1,933
1 to 2 years	**1,945**	12
	48,257	40,669
Portion classified as current assets	**(48,257)**	(40,669)
Non-current portion	**–**	–

The carrying amounts of the trade and bills receivables approximate to their fair values.

10. ISSUED CAPITAL

	30 June 2011 Unaudited *RMB'000*	31 December 2010 Audited *RMB'000*
Registered, issued and fully paid:		
67,017,528 domestic shares of RMB1 each	**67,018**	67,018
64,286,143 H shares of RMB1 each	**64,286**	64,286
	131,304	131,304

11. TRADE PAYABLES

An aged analysis of trade payables of the Group as at the balance sheet date, based on the invoice date, is as follows:

	30 June 2011 Unaudited *RMB'000*	31 December 2010 Audited *RMB'000*
Within 3 months	**12,177**	9,884
4 to 6 months	**745**	273
7 to 12 months	**348**	202
1 to 2 years	**911**	17
Over 2 years	**542**	216
	14,723	10,592

The trade payables are non-interest-bearing and are normally settled on credit terms ranging from 30 days to 90 days.

12. CONTINGENT LIABILITIES

The Group did not have any significant contingent liabilities as at 30 June 2011 (2010: Nil).

13. COMMITMENTS

(a) The Group did not have any significant capital commitments in respect of plant and machinery as at 30 June 2011 (2010: Nil).

(b) Pursuant to a research and development co-operation agreement (the "Research and Development Co-operation Agreement") dated 9 August 2004 entered into between the Group and the IBP, a shareholder of the Company, both parties will jointly engage in a pre-clinical research project for the development of a chemical drug, namely, Alprostadil for Injection. Upon completion of such pre-clinical research, the Group will have the right to obtain the ownership of the relevant clinical testing certificate and the production licence to be issued thereafter by the State Food and Drug Administration of the PRC, while the Group will have to complete the co-development of the pre-clinical research according to the Research and Development Co-operation Agreement. The assessed market value of the clinical research rights is subject to a cap of RMB5,000,000. Therefore, the maximum amount of consideration that the Group would pay to the IBP to acquire the clinical research rights would be RMB2,500,000.

On 12 April 2010, the Group and the IBP entered into a supplementary agreement to the above Research and Development Cooperation Agreement. Pursuant to this supplementary agreement, the Group paid RMB1,000,000 to the IBP during the year of 2010 and while the remaining RMB1,500,000 would be payable in the future years.

(c) On 9 December 2004, the IBP and the Group entered into an exclusive technology licensing agreement (the "Licensing Agreement") in regard to the production of diagnostic reagents by employing the technologies owned by the IBP (the "Reagent Technologies"). Pursuant to the Licensing Agreement, the Company is required to pay a fee of RMB500,000 per annum to the IBP for 20 years, commencing on the effective date of the Licensing Agreement.

14. RELATED PARTY TRANSACTIONS

(a) The Group had the following material transactions with related parties during the period:

		Six months ended 30 June	
		2011	2010
		Unaudited	Unaudited
	Note	***RMB'000***	*RMB'000*
Technical service fee	*(i)*	**250**	250

Note:

(i) Details of the technical service fee are set out in note 13(c) to the interim report.

(b) Compensation of key management personnel of the Group

	Six months ended 30 June	
	2011	2010
	Unaudited	Unaudited
	RMB'000	*RMB'000*
Short term employee benefits	**3,754**	3,571
Post-employment benefits	**143**	158
Total compensation paid to key management personnel	**3,897**	3,729

The directors are of the opinion that the above transactions were conducted in the ordinary course of business of the Group.

MANAGEMENT DISCUSSION AND ANALYSIS

Business Review for the First Half of 2011

As the implementation of social insurance policies and new medical policy reform have gradually intensified, the product structure of the medical industry was adjusting and upgrading, whereas enterprises were adjusting their commercial model. The medical market in China continued to expand. In particular, the market for in-vitro diagnostic reagents experienced significant growth. Several policies in relation to the PRC medical industry and in-vitro diagnostic reagents were under improvement, yet with fiercer competition in the overall medical industry.

During the first half of 2011, the growth in revenue from the Group's sales of diagnostic reagent products maintained steady growth in general with a relatively high level of gross profit margin. However, the operating profit dropped as a result of the decrease in sales of pharmaceutical products and increasing research and development cost and ongoing market investments.

With regard to research and development, we have implemented major tasks in the first half of the year. Firstly, we are endeavor to prepare for laboratory authentication 17025 and striving to be the first domestic enterprise that passes the authentication. Secondly, we have completed development of four products such as Lipoprotein(a) Calibrator and Specific protein Calibrator and met standard requirements of the provincial Food and Drug Administration, expecting to obtain registration certificates in the beginning of next year. Thirdly, we cooperated with Abbott Laboratories on the expansion of applicable reagent apparatuses on 42 biochemical products and 2 reference products. We are currently changing registrations of those products and will soon obtain permission. Fourthly, we have completed development of assay kits such as Sodium Kit and Potassium Kit in the first half year and are currently preparing for registration. Fifthly, the Group has finished development and pre-clinical research of four Deafness gene mutation detection kits in the first half year, the kits are currently under systemic assessment. The Group expects to obtain registration certificates of 3 kinds of products next year so as to achieve a breakthrough in the molecular diagnostics sector.

Financial Review for the First Half of 2011

Revenue for the six months ended 30 June 2011 was approximately RMB108 million, representing an increase of 3.1% as compared with approximately RMB105 million for the corresponding period last year. For the revenue of this period, approximately RMB86.1 million was generated from the sale of in-vitro diagnostic reagent products, accounting for 80% of the Group's total revenue and representing an increase of 16.9% as compared with RMB73.68 million for the corresponding period last year. As for pharmaceutical products, the revenue from the sale of Lumbrokinase capsules was RMB21.87 million, accounting for 20% of the Group’s total revenue and representing a decrease of 29.5% as compared with RMB31.03 million for the corresponding period last year.

For the six months ended 30 June 2011, profit before tax amounted to RMB8.6 million, representing a decrease of 34.1% over the corresponding period last year.

Profit attributable to shareholders of the Company for the six months ended 30 June 2011 was RMB6.2 million, representing a decrease of 39.4% as compared with RMB10.24 million for the corresponding period last year, which were mainly attributable to the decrease in sales of pharmaceutical products and an overall increase in the cost of production.

Prospect and Outlook

Looking forward, the Group is establishing a technology innovation system by forming the own innovation capabilities to build up the industry chain of in-vitro diagnostic reagents, which will enhance the core competitiveness of the Group. These tasks are expected to improve the business development and operating results of the Group in the future. As our instruments, immune diagnostic reagents and molecular diagnostics have obtained the registration certificates, the product structure of the Group will continue to be optimized, resulting in a well-developed commercial model.

The Board believes the introduction and implementation of the PRC medical industry reform will improve the market environment of the medical industry, generating new and bigger growth opportunities to the Group. The Group will proactively comply with the reform and endeavor to establish a competitive and sizable industry system, and emphasizes on our effort to strive for maximizing the interests of the shareholders.

OTHER INFORMATION

Capital Structure, Financial Position and Liquidity

The Group generally finances its operations with cash flows generated from sales, capital contributions from shareholders and bank borrowings. During the period, cash used in operating activities was approximately RMB14 million. There were no new issue of shares and no bank borrowings were obtained during the period.

As at 30 June 2011, the Group had cash and bank balances of approximately RMB181 million (as at 31 December 2010: approximately RMB203 million). The Group had corporated bonds amounted to RMB21 million as at 30 June 2011 and RMB20 million as at 31 December 2010 respectively. Such bonds are denominated in Renminbi and at fixed interest rates. The Group was in a net cash position of approximately RMB160 million (as at 31 December 2010: approximately RMB183 million). The gearing ratio (defined as total interest bearing borrowings over the equity attributable to shareholders of the Company) was 7.5% (as at 31 December 2010: 6.9%).

Purchase, Sale or Redemption of the Company's Listed Securities

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities during the six months ended 30 June 2011.

Securities Transactions by Directors

During the period under review, the Company has adopted the standards set out in Rules 5.48 to 5.67 of the GEM Listing Rules as the code of conduct regarding the Directors' securities transactions in securities of the Company. Having made specific enquiry to all Directors and the Company was not aware of any non-compliance with the required standards of dealings its code of conduct regarding securities transactions by Directors.

Audit Committee

The Company has established an audit committee with written terms of reference in compliance with the requirements as set out in Rules 5.28 and 5.29 of the GEM Listing Rules. The audit committee's primary duties are the review and supervision of the Company's financial reporting procedures and internal control system. The Group's unaudited condensed consolidated financial statements for the period have been reviewed by the audit committee with the three independent non-executive directors of the Company, namely Dr. Rao Yi, Dr. Hu Canwu Kevin and Mr. John Wong Yik Chung.

Code on Corporate Governance Practices

The Company always puts strong emphasis on the superiority, steadiness and rationality of corporate governance. Except for the deviation that Mr. Wu Lebin assumes the role of both the chairman of the Board and the president of the Company, the Company has complied with all the code provisions in the Code on Corporate Governance Practices as set out in Appendix 15 of the GEM Listing Rules (the

"Code") for the period ended 30 June 2011 by establishing a formal and transparent procedures to protect and maximise the interests of the shareholders during the period under review. The Board is of the view that it is in the best interests of the Group to have Mr. Wu, who has vast and solid experience in the medical industry to perform the dual role so that the Board can have the benefits of a chairman who is knowledgeable about the business of the Group and is most capable to guide and brief the Board in a timely manner on pertinent issues.

By order of the Board
Biosino Bio-Technology and Science Incorporation
Wu Lebin
Chairman

Beijing, the PRC, 12 August 2011

As at the date of this announcement, the Board of Directors of the Company comprises of:

Chairman and Executive Director
Mr. Wu Lebin (吳樂斌先生)

Vice Chairman and Non-executive Director
Dr. Gao Guang Xia (高光俠博士)

Executive Directors
Dr. Wang Lin (王琳博士) and Mr. Hou Quanmin (侯全民先生)

Non-executive Directors
Mr. Yao Fang (姚方先生), Mr. Qiao Zhicheng (喬志城先生), Mr. Zuo Zhihui (左志輝先生) and Mr. Wang Fu Gen (王福根先生)

Independent non-executive Directors
Dr. Rao Yi (饒毅博士), Dr. Hu Canwu Kevin (胡燦武博士) and Mr. John Wong Yik Chung (黃翼忠先生)

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the "Latest Company Announcements" page for at least 7 days from the date of its posting.